BioVex Completes $35 Million Financing

BioVex announced the completion of a Series E financing round (led by Triathlon Medical Ventures) and a venture debt transaction (with Oxford Finance Corporation and Silicon Valley Bank) that combined provide the Woburn, MA-based biotech with a total of $35 million. The company plans to use the funds to move its lead drug candidate, an anti-cancer treament, into a Phase 3 clinical trials and to take a genital-herpes vaccine into Phase 2 tests. BioVex previously closed $22 million of the Series E round, making it one of the top 10 New England venture deals of the second quarter.

Author: Rebecca Zacks

Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.